ѻý

SMART Strategy Lowers Asthma Exacerbation Risk

<ѻý class="mpt-content-deck">— LABA and LAMA also equally effective in meta-analysis
MedpageToday

Single maintenance and reliever therapy using an inhaled corticosteroid (ICS) and the long-acting β2-agonist formoterol was associated with a significantly lower risk for asthma exacerbations compared to separate ICS control and rescue with a short-acting β2-agonist, researchers reported.

In a review of 16 randomized randomized clinical trials, the therapeutic strategy known as SMART resulted in significantly fewer asthma attacks, hospitalizations and emergency department visits in patients age 12 years and older with persistent asthma, compared to use of the standard care treatment of using separate medications for asthma control and rescue.

Action Points

  • Single maintenance and reliever therapy using an inhaled corticosteroid (ICS) and the long-acting β2-agonist formoterol was associated with a significantly lower risk for asthma exacerbations compared to separate ICS control and rescue with a short-acting β2-agonist.
  • Note that in another meta-analysis of 15 randomized clinical trials examining LAMA as an add-on treatment to ICS, LAMA use was associated with a significantly lower risk for asthma exacerbations compared to placebo.

The meta-analysis was part of a larger review of asthma therapies requested by the National Heart, Lung and Blood Institute for the federal Agency for Healthcare Research and Quality (AHRQ).

Diana Sobieraj, PharmD, of the University of Connecticut, and colleagues, reported the findings in , along with findings from a separate analysis examining the use of long-acting muscarinic antagonists (LAMA) as an ICS add on therapy.

It has been 11 years since asthma guidelines in the U.S. were last updated by the National Asthma Education and Prevention Program, and those guidelines call for stepped approach to asthma pharmacotherapy. They also were issued before the availability of LAMA treatments for asthma.

In the review of SMART trials, which included roughly 22,500 patients (mean age 42), the strategy was associated with a reduced risk of asthma exacerbations compared with the same dose of inhaled corticosteroids and LABA as the controller therapy (RR 0.68, 95% CI 0.58-0.80; risk difference −6.4%, 95% CI −10.2% to −2.6%) and a higher dose of inhaled corticosteroids and LABA as the controller therapy (RR 0.77, 95% CI 0.60 to 0.98).

Similar results were seen when SMART was compared with inhaled corticosteroids alone as the controller therapy.

"We found that the combined use of inhaled corticosteroid and LABA as both controller and rescue therapy in patients with persistent asthma who were age 12 and older significantly reduced the risk of asthma exacerbations compared to traditional ICS and LABA with albuterol used as rescue medication," Sobieraj told ѻý.

The meta-analysis of 15 randomized clinical trials examining LAMA as an add-on treatment to ICS (n=7,122 patients) showed LAMA use to be associated with a significantly lower risk for asthma exacerbations compared to placebo (RR 0.67, 95% CI 0.48-0.92).

When LAMA was compared to LABA as an ICS add-on therapy, no significant reduction in exacerbation risk was seen (RR 0.87, 95% CI 0.53-1.42).

Triple therapy was not significantly associated with a lower risk of exacerbations.

Sobieraj noted that the available evidence suggests no significant difference between LAMAs and LABAs with regard to their impact on asthma exacerbations, asthma symptoms or lung function.

"But the studies we reviewed are not robust enough to determine whether one of these two classes of long-acting bronchodilators may be better than the other," she said.

In an editorial published with the two meta-analyses, Jerry Krishnan, MD, PhD, of the University of Illinois, Chicago; and David Au, MD, of the University of Washington, Seattle, wrote that the findings should inform the update of the 2007 Expert Panel Report 3 (EPR-3) asthma treatment guidelines.

"Updates of EPR-3 are planned, and the results of the meta-analyses of inhaled tiotropium by Sobieraj et al. suggest that LAMA should be offered as a treatment option in steps 3 through 6 in the updated guidelines," they wrote.

"Such changes to the EPR-3 guidelines would help to harmonize the approval by the FDA for inhaled tiotropium and the clinical guidelines in the United States. For patients and clinicians, the results from these meta-analyses suggest that dual therapy with scheduled doses of inhaled corticosteroids and LABA or inhaled corticosteroids and LAMA should help reduce the risk of future asthma exacerbations in patients with inadequate asthma control when using inhaled corticosteroids alone."

Disclosures

The two meta-analyses were funded by the Agency for Healthcare Research and Quality.

Editorial writer Jerry Krishnan reported receiving fees from Sanofi for participation in an independent data monitoring committee. Editorial writer David Au reported receiving fees from Novaritis for participating in a data monitoring committee and serving as a consultant to Gilead Sciences.

Primary Source

JAMA

Sobieraj DM, et al "Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis" JAMA 2018; DOI: 10.1001/jama.2018.2757.

Secondary Source

JAMA

Sobieraj DM, et al "Association on inhaled corticosteroids and long-acting B-agonists as controller and quick relief therap wth exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis" JAMA 2018; DOI: 10.1001/jama.2018.2769.

Additional Source

JAMA

Krishnan JA and Au DH, et al. "Time to converge FDA decisions and evidence syntheses for long-acting muscarinic antagonists and SMART in guidelines for the treatment of asthma" JAMA 2018; DOI: 10.1001/jama.2018.2029.